Stephens Consulting’s Aldeyra Therapeutics ALDX Stock Holding History

Stephens Consulting’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$3.83K	–	418
2025 Q2	$3.83K	Hold	1,000	–	–	﹤0.01%	410
2025 Q1	$5.75K	Hold	1,000	–	–	﹤0.01%	377
2024 Q4	$4.99K	Hold	1,000	–	–	﹤0.01%	411
2024 Q3	$5.39K	Hold	1,000	–	–	﹤0.01%	393
2024 Q2	$3.31K	Hold	1,000	–	–	﹤0.01%	452
2024 Q1	$3.27K	Hold	1,000	–	–	﹤0.01%	396
2023 Q4	$3.51K	Hold	1,000	–	–	﹤0.01%	400
2023 Q3	$6.68K	Hold	1,000	–	–	﹤0.01%	354
2023 Q2	$8.39K	Hold	1,000	–	–	﹤0.01%	326
2023 Q1	$9.93K	Hold	1,000	–	–	0.01%	318
2022 Q4	$6.96K	Hold	1,000	–	–	﹤0.01%	342
2022 Q3	$5.34K	Hold	1,000	–	–	﹤0.01%	401
2022 Q2	$3.99K	Hold	1,000	–	–	﹤0.01%	423
2022 Q1	$4.45K	Sell	1,000 -1,000	-50%	-$3.98K	﹤0.01%	450
2021 Q4	$8K	Buy	+2,000	New	+$15.3K	0.01%	425

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Stephens Consulting's ALDX Position: Q3 2025 in Review

Stephens Consulting sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 1,000 shares — an estimated $3.83K sold.

Stephens Consulting first reported a position in ALDX in Q4 2021 and held it in 15 quarters. The position peaked at $9.93K in Q1 2023. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

Stephens Consulting reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 1,000 Aldeyra Therapeutics shares in Q3 2025, an estimated $3.83K.
Stephens Consulting first reported a position in Aldeyra Therapeutics in Q4 2021 and held it in 15 quarters.
Stephens Consulting's Aldeyra Therapeutics position peaked at $9.93K in Q1 2023.
130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.